In an investigation of the effects of anti-inflammatory drugs on AD, Cui et al. [144] found that the activation of LXR significantly reduced validated markers in APP/PS1 mouse brains by inhibiting the expression of NF-κB and decreasing the activation of microglia and astrocytes. Here, NFKB1 is linked to Alzheimer disease.